Stay updated with breaking news from Michael Erman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia...
That’s more than double what the government currently pays for it.
Pfizer on Wednesday said it will set the US price for its COVID-19 antiviral treatment Paxlovid at nearly $1400 per five-day course when it moves to commercial sales after government stocks run out, more than double what the government currently pays for it.
Pfizer on Wednesday said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government stocks run...
(Reuters) -Pfizer on Wednesday said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government stocks run out, more than double what the government currently pays for it. The new list price, which does not include rebates and other discounts to insurers and pharmacy benefit managers, is $1,390 per course, Pfizer said in an emailed statement. The U.S. government paid around $530 per course for Paxlovid it has made available to Americans at no cost.